Tocilizumab 20 Mg/mL Intravenous Solution
Sponsors
Christian Hassager, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions
Esophageal AdenocarcinomaGraves OphthalmopathyHeart ArrestOesophageal AdenocarcinomaOut-Of-Hospital Cardiac ArrestResectable CarcinomaSystemic Inflammatory Response Syndrome
Phase 2
IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest
CompletedNCT03863015
Start: 2019-03-04End: 2020-06-30Updated: 2020-08-21
Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy
Active, not recruitingNCT04554771
Start: 2021-01-27End: 2028-04-10Updated: 2024-07-29
Tocilizumab in Active Moderate-severe Graves' Orbitopathy
NCT04876534
Start: 2019-12-18End: 2023-12-18Target: 64Updated: 2022-08-04